Advantages of OCT

Article

According to Professor Albert Augustin, OCT is mandatory in research and very helpful in avoiding unnecessary treatment.

According to Professor Albert Augustin, OCT is mandatory in research and very helpful in avoiding unnecessary treatment. He described his viewpoint in this month's cover feature on retina imaging.

"One of the major advantages of SD-OCT is the ability to create 3D samples of the tissue…" Prof. Augustin said. This enables more insight and better understanding as much more detail can be seen.

Not only can OCT technology assist in a surgeons preoperative judgement of a patient but it can also help with the decision on treatment regimen. In planning surgery a physician can use SD-OCT to perform a correct prognosis on a patient as it will allow them to view any alterations occurring, for example, in the RPE. Once the correct prognosis has been made then the level of detail gained form an OCT image can be used to guide the practitioner to the appropriate procedure.

Surgical follow-up of a patient can also benefit from OCT. In cases of retinal vein occlusion it is possible to view bright reflective dots that are inflammatory markers that should react on the implantation of dexamethasone slow release devices. "Differences in the numbers of these dots can be assessed by OCT during the follow up of a RVO patient," said Prof. Augustin.

OCT is interesting in research and clinical follow up in Prof. Augustin's opinion. However, he stressed that in cases of AMD OCT is mandatory and the images must be viewed carefully. It is simple to misinterpret results leading to an incorrect diagnosis and mistreatment of patients.

In conclusion, Prof. Augustin said, "I would like to encourage the use of OCT, especially in macular disesases."

If you would like to read more about the advantages of OCT, see Prof. Augustin's full article in the May print issue of OTEurope.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.